FDA Inspection 1008344 — Halo Pharmaceutical, Inc. D/B/A Cambrex Whippany
The FDA completed an inspection of Halo Pharmaceutical, Inc. D/B/A Cambrex Whippany on Mar 20, 2017 in Whippany, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 20, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Whippany, NJ (United States)